Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the ISBP 2022 Conference
September 15 2022 - 4:20PM
Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the
“Company”), an agricultural bioscience company, today announced
that its Chief Science Officer Dr. Kristi Snell will present during
the International Symposium on Biopolymers (“ISBP”) 2022
Conference. The event is taking place September 12 through
September 16, 2022 in Sion, Switzerland.
Dr. Snell will make a presentation on Friday, September 16,
during the session entitled “Industrial Feedstocks and Polymer
Production” scheduled for 9:20 am to 11:00 am local time (3:20 am
to 5:00 am ET). Her presentation entitled “Breakthroughs in Plant
Based Polyhydroxybutyrate (PHB) Production” will describe the
successful engineering of a bacterial pathway for producing PHB in
the cytosol of Camelina seed.
Yield10 researchers are conducting a program intended to produce
sustainable, low-cost PHA bioplastic materials in the seed of the
Camelina plant. In a patent application filed in 2019, Yield10
described a new technology solution for deploying the PHB pathway
in Camelina. Using this approach, Yield10 obtained Camelina plants
showing up to 10.2 percent PHB in seed that had good emergence and
survival in growth chambers. Subsequent field tests with prototype
Camelina PHB containing lines have shown approximately six percent
PHB in the seed in two consecutive years. In 2022, Yield10 planted
PHB producing Camelina at acre-scale and has harvested the plants
for PHB extraction, product prototyping, sampling and other
business development activities. The development of elite PHA
Camelina lines with yields in the 10 to 20 percent range is
ongoing, as well as the engineering of PHA copolymers in
Camelina.
“We have successfully demonstrated proof of concept for
producing PHA bioplastics in Camelina seed by leveraging advanced
tools in synthetic biology,” said Kristi Snell, Ph.D., Chief
Science Officer of Yield10 Bioscience. “This spring we grew
prototype PHA Camelina at acre-scale. We have now harvested the
crop and plan to extract the PHA from seed for business development
purposes. We have also engineered PHA production in winter Camelina
lines which we plan to test for the first time in our 2022/2023
winter field trial program. As we move this program forward, we are
pursuing multiple strategies to achieve our goal of reaching PHA
yields of 10 to 20 percent in Camelina seed in field grown
plants.”
Learn more about the ISBP 2022 on the conference website. A copy
of Dr. Snell’s slide deck is available on the Yield10 Bioscience
investor relations website.
Background on PHA Bioplastics
Global plastic waste is estimated at 380 million metric tons per
year. The largest market for plastics today is for packaging
materials, and it accounts for nearly half of all plastic waste
generated globally, where most of it is never recycled or
incinerated. We believe there may be significant market opportunity
for producing PHA biomaterials in Camelina in the future. PHA
biomaterials (PHAs) are natural microbial high molecular weight
polymeric storage polymers. These polymers are natural polyesters
and can be recovered from the microbes that produce them and
processed using standard plastics processing equipment into a range
of product forms. The production of PHA bioplastics in Camelina
could represent an entirely new market opportunity for farmers.
This opportunity could provide economic returns for farmers to
justify large acreage adoption of Camelina as a cover crop and
enable the low-cost production of this product for new markets
including water treatment and sustainable biodegradable plastics
replacement applications.
About Camelina sativa
Camelina sativa, commonly known as Camelina or false flax, is an
annual oilseed plant in the mustard family that is native to
Europe. Camelina has the potential to replicate the development of
modern canola from rapeseed on an accelerated timeline based on
modern technologies, including genomics and genome editing.
Additionally, Camelina grows on marginal lands, displays early
maturation, has enhanced drought and cold tolerance, and requires
fewer inputs than other oilseed crops. With social conscience and
sustainability in mind, Yield10 is leveraging its innovations in
Camelina to use it as a platform crop for producing low-carbon
feedstock oil for renewable fuel; omega-3 nutritional oils;
high-protein meal; and PHA bioplastic.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
that is using its differentiated trait gene discovery platform, the
“Trait Factory”, to develop improved Camelina varieties for the
production of proprietary seed products, and to discover high value
genetic traits for the agriculture and food industries. Our goals
are to efficiently establish a high value seed products business
based on developing superior varieties of Camelina to produce
biofuel feedstock oils, PHA bioplastics and omega-3 (DHA+EPA) oils
and to license our yield traits to major seed companies for
commercialization in major row crops, including corn, soybean and
canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds
Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, the Company’s plans with respect to Camelina business
development and field testing; the Company’s goals relating to PHA
yields in Camelina seed; and the Company’s beliefs about the market
opportunity for PHA biomaterials and bioplastics,
constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated, including the risks and uncertainties detailed in
Yield10 Bioscience's filings with the Securities and Exchange
Commission. Yield10 assumes no obligation to update any
forward-looking information contained in this press release or with
respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Sep 2023 to Sep 2024